Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.54 |
| ▸ | GAA | P10253 | 3/20 | 0.54 |
| ▸ | POLB | P06746 | 2/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.54 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | HTR7 | P34969 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | TTR | P02766 | 1/20 | 0.42 |
| ▸ | KMO | O15229 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | XPO1 | O14980 | 1/20 | 0.42 |
| ▸ | RORC | P51449 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12800749 | 0.84 | ALDH1A1 (0.62) | KDM4EGAAPOLBHSD17B10NR4A1 | |
| SCHEMBL18077326 | 0.84 | KDM4E (0.50) | KDM4EGAAPOLBHSD17B10NR4A1 | |
| SCHEMBL31467812 | 0.84 | KDM4E (0.50) | KDM4EGAAPOLBHSD17B10NR4A1 | |
| SCHEMBL29784244 | 0.83 | KDM4E (0.66) | KDM4EGAAPOLBHSD17B10NR4A1 | |
| SCHEMBL1398597 | 0.83 | KDM4E (0.66) | KDM4EGAAPOLBHSD17B10NR4A1 | |
| SCHEMBL1663434 | 0.83 | GAA (0.56) | KDM4EGAAPOLBHSD17B10NR4A1 | |
| SCHEMBL1664707 | 0.83 | HSD17B10 (0.56) | KDM4EGAAPOLBHSD17B10NR4A1 | |
| SCHEMBL382272 | 0.82 | ALDH1A1 (0.59) | KDM4EHSD17B10TSHRL3MBTL1MEN1 | |
| SCHEMBL8806160 | 0.82 | GAA (0.69) | KDM4EGAAPOLBHSD17B10TSHR | |
| SCHEMBL27783744 | 0.81 | GAA (0.53) | KDM4EGAAPOLBHSD17B10NR4A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2314586-B1 | 2-Acylaminothiazole derivative or salt thereof | ASTELLAS PHARMA INC (JP) | 2016-09-14 | — | — | EP | disclosed |
| US-8765764-B2 | 2-acylaminothiazole derivative or salt thereof | ASTELLAS PHARMA, INC. (JP) | 2014-07-01 | — | — | US | disclosed |
| EP-1466912-B1 | 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC (JP) | 2013-04-24 | — | — | EP | disclosed |
| US-20130079351-A1 | 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA, INC. (JP) | 2013-03-28 | — | — | US | disclosed |
| US-8338429-B2 | 2-acylaminothiazole derivative or salt thereof | ASTELLAS PHARMA, INC. (JP) | 2012-12-25 | — | — | US | disclosed |
| EP-2314586-A1 | 2-Acylaminothiazole derivative or salt thereof | Astellas Pharma Inc. (JP) | 2011-04-27 | — | — | EP | disclosed |
| US-20100222329-A1 | 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2010-09-02 | — | — | US | disclosed |
| US-20100222361-A1 | 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2010-09-02 | — | — | US | disclosed |
| US-7638536-B2 | N-[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl]-3-fluoro-4-hydroxybenzamide; nonpeptide c-mpl ligand; low immunogenicity; proliferate human c-mpl-Ba/F3 cells; increase platelets by promoting the formation of megakaryocytic colonies; orally | ASTELLAS PHARMA INC. (JP) | 2009-12-29 | — | — | US | disclosed |
| US-20050153977-A1 | 2-Acylaminothiazole derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2005-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050153977-A1 | 2-Acylaminothiazole derivative or salt thereof | MPL, JAK2, ABL1 | KDM4E 1499/4885GAA 3757/4885POLB 3833/4885 |
| US-20130079351-A1 | 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF | MPL, JAK2, ABL1 | KDM4E 1499/4885GAA 3757/4885POLB 3833/4885 |
| US-20100222329-A1 | 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF | MPL, JAK2, ABL1 | KDM4E 1499/4885GAA 3757/4885POLB 3833/4885 |
| US-20100222361-A1 | 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF | MPL, JAK2, ABL1 | KDM4E 1499/4885GAA 3757/4885POLB 3833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.